Amerikanische Gesellschaft für Hirudotherapie

Irritable Bowel Syndrome, Pain-Predominant (Investigational Adjunct)

Investigational adjunct for pain-predominant IBS refractory to dietary and pharmacologic therapy; low-FODMAP diet, antispasmodics, low-dose tricyclic antidepressants, and cognitive behavioral therapy or gut-directed hypnotherapy remain evidence-based.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for irritable bowel syndrome, pain-predominant. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
Welche Evidenz existiert?
Tier C (investigational). No controlled trials. Evidence-based first-line management is dietary intervention (low-FODMAP diet has the strongest evidence), antispasmodics (hyoscyamine, peppermint oil), tricyclic antidepressants or SNRIs for pain, soluble fiber for constipation-predominant subtypes, eluxadoline or rifaximin for diarrhea-predominant or mixed subtypes, gut-directed hypnotherapy, and cognitive behavioral therapy.
Hauptrisiken
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Bowel symptom flare around session days from stress and dietary disruption
  • Distraction from evidence-based dietary and pharmacologic interventions
Wer dies nicht in Betracht ziehen sollte
  • Patients with alarm features (rectal bleeding, weight loss, anemia, age over 50 without prior workup) — need GI workup first
  • Patients who have not tried low-FODMAP diet, antispasmodics, or appropriate medications
  • Patients with possible inflammatory bowel disease or celiac disease that has not been ruled out
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with severe anemia (hemoglobin under 10 g/dL)
  • People with an active infection at the planned application site
Was Sie Ihren Kliniker fragen sollten
  • Have I had appropriate IBS workup excluding IBD, celiac, and other mimics?
  • Have I tried low-FODMAP diet under a dietitian's guidance?
  • Have I tried antispasmodics, peppermint oil, or a tricyclic antidepressant?
  • Have CBT or gut-directed hypnotherapy been considered?
  • What is the published evidence base for leeches in IBS?
  • How will success be measured?
Wann dringende medizinische Versorgung suchen
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Rectal bleeding, black or tarry stools, unintentional weight loss
  • Nighttime diarrhea waking from sleep
  • Severe abdominal pain not typical of IBS pattern

Was dies NICHT bedeutet

  • It does not mean leech therapy is FDA-cleared for IBS — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace low-FODMAP diet, antispasmodics, or psychological therapies.
  • It does not change the gut-brain axis dysregulation underlying IBS.
  • It does not exclude or treat IBD, celiac, or other mimics.
  • It does not have controlled-trial evidence in IBS.

Clinical Profile

Category
gastrointestinal
ICD-10
K58.0, K58.1, K58.2, K58.8, K58.9
Safety tier
medium

Evidence Summary

Irritable bowel syndrome (Rome IV) is recurrent abdominal pain associated with defecation or change in bowel habits, in the absence of structural disease. Pain-predominant phenotypes overlap with IBS-D, IBS-C, and IBS-M. Evidence-based management is dietary trial (low-FODMAP, with structured reintroduction), antispasmodics (hyoscine, peppermint oil), low-dose tricyclic antidepressants for pain, SSRIs for IBS-C with mood comorbidity, and gut-directed hypnotherapy or cognitive behavioral therapy with substantial RCT support. Linaclotide, plecanatide, and lubiprostone for IBS-C; eluxadoline, rifaximin, and alosetron for IBS-D. No published controlled trials of hirudotherapy exist for IBS. Abdominal placement in central European literature is anecdotal without efficacy data.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Alarm features (weight loss, GI bleeding, anemia, family history of GI cancer) — workup first
  • Inflammatory bowel disease
  • Active gastroenteritis or post-infectious IBS within 8 weeks
  • Stoma, ventral hernia, or abdominal wall pathology at placement site
  • Pregnancy or lactation

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Irritable Bowel Syndrome, Pain-Predominant (Investigational Adjunct) — Hirudotherapy Evidence | ASH